Back to Results

Jay S. Duker, MD Accepting New Patients Virtual Appointments Available

Loading ...

Programs + Specialties
Training + Education Jefferson Medical College of Thomas Jefferson University; Vitreoretinal Diseases and Surgery and Intraocular Tumors,Wills Eye Hospital; Professor of Ophthalmology, Tufts University School of Medicine;
Board Certifications American Board of Ophthalmology
NPI # 1508820838
Gender Male
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Loading ...


Loading ...

New England Eye Center - Boston
800 Washington St.
Box 450
Boston, MA 02111
Phone #: 617-636-4604
Fax #: 617-636-4866

1992 – American Academy of Ophthalmology, Honor Award
2003 – American Academy of Ophthalmology, Senior Achievement Award
2010 – American Society of Retina Specialists, Honor Award
2013 – American Society of Retina Specialists, Senior Honor Award
2015 – American Academy of Ophthalmology, Life Achievement Honor Award
2015 – Brazilian Society of Retina and Vitreous Honor Award
2019 - Vicki and Jack Farber Vision Research Award, Wills Eye Hospital

Books and Chapters
Yanoff M, Duker JS, eds. Ophthalmology. Mosby, London, 4 Editions from 1999-2014.

Duker JS, Waheed NK, Goldman DR. Handbook of Retinal OCT. Elsevier, Saunders, 2014.

Duker JS, Witkin AJ, eds. Age-Related Macular Degeneration – Current Management.Slack Incorporated, NJ, 2015.

Laver N V, Sitko K, Duker JS, Farhat NA. Ocular Tumors. In: Linda M. McManus, Richard N. Mitchell, editors. Pathobiology of Human Disease. San Diego: Elsevier; 2014. P. 2179-2200.

Dr. Duker has over 250 papers published in peer-reviewed journals. His manuscripts have appeared in high impact journals and one of them has been among the top 10 referenced ophthalmology research papers over the past five years. Here are a few recent examples:

Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. Dec 2013;120(12):2611-9.

Duker JS, Moshfeghi AA. Ocriplasmin: A Medical or Surgical Therapy? Retina. Nov/Dec 2013;33(10):2001-2. Lally DR, Duker JS, Mignano JE, Martin S, Witkin AJ. Regression of Choroidal Metastasis from Breast Carcinoma Treated with Gamma Knife Radiosurgery. JAMA Ophthalmology. October 2014;132(10):1248-1249.

Fein JG, Branchini LA, Manjunath V, Regatieri CV, Fujimoto JG, Duker JS. Analysis of Short-Term Change in Subfoveal Choroidal Thickness in Eyes with Age-Related Macular Degeneration using Optical Coherence Tomography. OSLI Retina. Jan/Feb 2014;45(1):32-7. Mehta M, Rasheed RA, Duker JS, Reichel E, Feinberg E, Husain D, Foster CS, Laver NV. Vitreous Evaluation: A Diagnostic Challenge. Ophthalmology. Mar 2015;122(3):531-7.

Inoue M, Jung JJ, Balaratnasingam C, Dansingani KK, Dhrami-Gavazi E, Suzuki M, de Carlo TE, Shahlaee A, Klufas MA, El Maftouhi A, Duker JS, Ho AC, Quaranta-El Maftouhi M, Sarraf D, Freund KB, COFT-1 Study Group. A Comparison Between Optical Coherence Tomography Angiography and Fluorescein Angiography for the Imaging of Type 1 Neovascularization. IOVS. July 2016;57:314-23.

Jay S. Duker, M.D. is a Professor of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine in Boston, Massachusetts. He served as the Chair of the Ophthalmology Department at Tufts between 2001 and 2021.

Through his varied ophthalmology-related activities spanning four decades of practice, he has developed a local, regional, national, and international reputation as a highly successful clinician, surgeon, diagnostician, educator, researcher, administrator, and entrepreneur.

American Medical Association
American Academy of Ophthalmology
Massachusetts Society of Eye Physicians and Surgeons
Massachusetts Medical Society
FRAME Fluorescein Angiography Club
International Academy of Sports Vision
American Society of Retina Specialists
New England Ophthalmology Society
Association of University Professors in Ophthalmology
Principal Founder and Director, SurgiSite Boston
Director and Founder, Hemera Biosciences
Director and Chair of the Board, Sesen Bio
Director, EyePoint Pharma
Founding Editor-in-Chief, International Journal of Retina and Vitreous
Editorial Board of OSLI Retina, Retina Cases and Brief Reports, and Investigative Ophthalmology and Visual Sciences

Boston Magazine Top Doctors 2023

2023 “Top Doctors” at Tufts Medical Center

See our Top Doctors
Boston Magazine 2022 Top Doctors

2022 “Top Doctors” at Tufts Medical Center

See our Top Doctors
Top Doctor 2021

2021 “Top Doctors” at Tufts Medical Center

See our Top Doctors
Top Doctors Boston Magazine 2020

2020 “Top Doctors” at Tufts Medical Center

See our Top Doctors
Eli Peli, MD

Vision Rehabilitation Service co-director Eli Peli, MSc, OD selected to receive the AAO Charles F. Prentice Medal Award.

Vision Rehabilitation Service co-director Eli Peli, MSc, OD selected to receive the AAO Charles F. Prentice Medal Award. - Read More
Boston Magazine 'Top Doctor' Award 2016

Boston magazine honors 2016 “Top Doctors” at Tufts Medical Center.

2016 Boston magazine Top Doctors
Boston Magazine 'Top Doctor' Award 2015

Boston magazine honors 2015 “Top Doctors” at Tufts Medical Center.

2015 Boston magazine Top Doctors
Boston Magazine 'Top Doctor' Award 2017

Boston Magazine honors 2017 “Top Doctors” at Tufts Medical Center.

2017 Boston Magazine Top Doctors
Dr. Clarissa Yang on the cover of 2019 Boston Magazine Top Doctor issue.

2019 “Top Doctors” at Tufts MC and Tufts Medical Center

See our Top Doctors
Five white stars

What do the star ratings on physician profiles mean?

Learn about the program

Dr. Duker's current full time position is Chief Operating Officer (COO) of EyePoint Pharmaceuticals, a publicly traded biotech company that specializes in long term drug delivery to the eye. Dr. Duker is the founder of several successful businesses including a the fifth busiest independent ophthalmic ambulatory surgery center in the United States, SurgiSite Boston. Dr. Duker is a founder of Hemera Biosciences, a clinical-stage biotech company developing treatments of eye disease through complement inhibition using a gene therapy delivery system that was acquired by Janssen in 2020, and the Boston Image Reading Center (BIRC).